Figure 6. Effects of aDBS compared to cDBS on both subjective and objective metrics of motor symptoms and quality of life.

a-b, Self-reported symptom duration from daily questionnaires. a, aDBS resulted in a significantly decreased percentage of awake hours experiencing the most bothersome symptom (each patient p<0.001). b, Even while reducing time with the most bothersome motor symptom, aDBS resulted in either no significant change (pat-1: p=0.56, pat-2: p=1) or an improvement (pat-3: p=0.02) in the percentage of awake hours experiencing the opposite symptom. c, Quality of life, as measured by the EQ-5D, was improved for two of three patients (pat-1 and pat-2: p<0.001). The third patient reported very high quality of life scores, with minimal reported variance for both cDBS and aDBS. d-e, Wearable monitor scores demonstrating the decreases in symptom intensity fluctuations. Only patients 1 and 3 are displayed, as patient 2’s bothersome and opposite symptoms were not measurable by a wearable device. Laterality refers to the brain hemisphere where aDBS was applied (and therefore contralateral motor sign measurement). d, Fluctuation scores represent differences between wearable scores during hypo- and hyperkinetic states defined by the neural signal. Fluctuations were reduced during aDBS compared to cDBS, representing a stabilized clinical profile throughout the day (pat-1: p<0.001, pat-3R: p=0.005, pat-3L: p=0.046). e, Similar improvements in the dyskinesia fluctuation score were seen in two of three hemispheres with aDBS (pat-1: p=0.04, pat-3R: p=0.03). Error bars reflect standard error of the mean.